1. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206 - Abstract
(Browse Categories/Renal Cancer)

...that binds to vascular endothelial growth factor (VEGF) and has activity in metastatic renal cell carcinoma (RCC). Interferon alfa (IFN) is a historic standard first-line treatment for RCC. A prospect...

2. √ Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma
(Browse Categories/Renal Cancer)

... read other UroToday.com Editors Picks UroToday.com Renal Cancer Section Sunitinib Articles on UroToday.com Interferon Alfa Articles on UroToday.com ...

3. Medroxyprogesterone, Interferon Alfa-2a, Interleukin 2, or Combination of Both Cytokines in Patients with Metastatic Renal Carcinoma of Intermediate Prognosis : Results of a Randomized Controlled Trial - Abstract
(Browse Categories/Renal Cancer)

Université de Lyon, Department of Medical Oncology and Cytokines & Cancer Research Unit, Leon Berard Center, INSERM U590, Lyon, France Few randomized trials have compared the survival benefit

4. Sorafenib with Interferon Alfa-2b as First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group - Abstract
(Browse Categories/Renal Cancer)

...th and Science University, Portland, OR, USA This phase II study evaluated the activity of combined treatment with interferon alfa-2b and sorafenib, a Raf and multiple receptor tyrosine kinase inhibit...

5. ASCO 2008 Annual Meeting - Phase II Trial of Meloxicam, a COX-2 Inhibitor, and Interferon Alfa in Patients with Metastatic Renal Cell Carcinoma
(Conference Coverage/ASCO 2008 - Kidney Cancer Abstracts)

Abstract No.: 16003 Citation: J Clin Oncol 26: 2008 (May 20 suppl; abstr 16003) Author(s): N. Shinohara, T. Abe, A. Sazawa, K. Nonomura, Hokkaido Immunotherapy Research Group

6. √ Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
(Browse Categories/Renal Cancer)

√ Editor's Pick:     BERKELEY, CA (UroToday.com) - Temsirolimus is a specific inhibitor of mTOR kinase a key component of intracellular signaling involved in cell proliferation.Via

7. Phase II Trial of Sorafenib Plus Interferon Alfa-2b as First- or Second-Line Therapy in Patients with Metastatic Renal Cell Cancer - Abstract
(Browse Categories/Renal Cancer)

...lob@duke.edu We undertook this study to determine the activity and tolerability of sorafenib administered with interferon alfa-2b (IFN-alpha-2b) as first- or second-line therapy in metastatic rena...

8. Quality of Life in Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib or Interferon Alfa: Results from a Phase III Randomized Trial - Abstract
(Browse Categories/Renal Cancer)

... In an international, randomized phase III trial, sunitinib demonstrated statistically significant efficacy over interferon alfa (IFN-alpha) as first-line therapy in patients with metastatic renal c...

9. Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma - Abstract
(Browse Categories/Renal Cancer)

...e survival (PFS), overall best response, adverse events (AEs), and patient-reported outcomes with sorafenib versus interferon alfa-2a (IFN-alpha-2a) in patients with untreated, advanced renal cancer. ...

10. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma - Abstract
(Browse Categories/Renal Cancer)

...aacute; d'Oncologia, Barcelona, Spain. A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-alpha) in progression-free survival (primary end point) as first...

11. ASCO 2008 Annual Meeting - A Randomized Phase II Trial of Sorafenib Versus Sorafenib Plus Low-Dose Interferon-Alfa: Clinical Results and Biomarker Analysis
(Conference Coverage/ASCO 2008 - Kidney Cancer Abstracts)

...ng progression-free survival (PFS) in pts with mRCC after cytokine failure. We have previously shown that low-dose interferon alfa (IFN-α) was comparable in efficacy and was better tolerated than int...

12. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis - Abstract
(Browse Categories/Renal Cancer)

Department of Genitourinary Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. The objective of this study was to independently evaluate the objective response r

13. European Commission Grants Conditional Marketing Authorization To Pfizer’s Sutent®
(Browse Categories/Renal Cancer)

...ion for advanced and/or metastatic renal cell carcinoma (mRCC), a type of advanced kidney cancer, after failure of interferon alfa and interleukin-2 therapies. Sutent was given conditional approval fo...

14. Renal Cell Cancer – Abstract
(Browse Categories/Renal Cancer)

...lar have been utilized as therapeutic targets. Sunitinib malate, sorafenib tosylate, temsirolimus, and bevacizumab/interferon alfa have improved clinical outcomes in randomized trials. Other antiangio...

15. Prognostic Factors for Survival in Patients with Metastatic Renal Cell Carcinoma Reviewed
(Browse Categories/Renal Cancer)

...ntified five prognostic factors that correlated with overall survival in patients with metastatic RCC treated with interferon alfa as initial systemic therapy. The factors were Karnofsky performance ...